ClinicalTrials.gg
RecruitingNCT05867771Updated May 22, 2023

A Study of PM1022 in Patients With Advanced Tumors

A Phase 1/2 interventional study of PM1022 in Advanced Tumors, sponsored by Biotheus Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Apr 2022, registered May 2023).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study incluces a phase I study to evaluate the tolerance, safety, pharmacokinetic characteristics and preliminary efficacy of PM1022 in patients with advanced tumors and a phase IIa study to investigate the efficacy of PM1022 in patients with advanced tumors.

Read the detailed description

PM1022 is a recombinant humanized anti-PDL1 and anti-TIGIT bispecific antibody. This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of PM1022 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.

02

Conditions studied

  • Advanced Tumors
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation in clinical study; fully understand the study and sign voluntarily; willing to follow and able to complete all test procedures;
  • No gender limit, aged 18 to 75 years (boundary values included);
  • Subjects with malignant tumor confirmed by histology or cytology;
  • Adequate organ function;
  • score was 0-1;
  • Expected survival >=12 weeks;
  • According to V1.1, there are at least one evaluable or measurable tumor lesion;
  • All subjects should undergo of tumor lesions during the screening; if biopsy is not possible, formalin-fixed-paraffin-embedded (FFPE)-processed tumor samples closest to the start of study treatment should be provided for biomarker analysis;
  • Pre-menopausal female subjects with negative blood pregnancy results within 7 days prior to the study treatment, and agree to abstain from sex or use medically approved effective measures for 5 months from the date of signing the informed consent form to the end of the last medication;
  • Male subjects are willing to remain abstinent from sex or use medically approved highly effective contraception from the time of signing the informed consent to 5 months after the end of the last medication, and do not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic, severe allergy to drugs or known allergy to any component of the drug in this study;
  • Previous exposure to immune costimulatory molecule agonists or of patients in phase I;
  • Patients who have grade >=3 immune-mediated adverse event (AE) that associated with a prior immunotherapy;
  • Adverse reactions to previous antitumor therapy have not recovered to V5.0 rating \<= 1;
  • Current definite interstitial lung disease or non-infectious pneumonitis, except for local radiotherapy;
  • Received the following treatments or medications before starting treatment:

    1. Underwent major organ surgery (excluding needle ) within 28 days before starting study treatment, or required elective surgery during the trial;
    2. was administered within 28 days before the study began;
    3. Received anti-tumor therapy within 4 weeks before the first dose;
    4. Received systemic within 14 days prior to study initiation;
  • Cerebral parenchymal or meningeal metastasis with clinical symptoms were deemed unsuitable for inclusion by the investigator;
  • Patients with active disease or a history of autoimmune disease with potential for relapse;
  • Patients with other active within 5 years prior to initiation of study treatment;
  • History of severe cardiovascular and cerebrovascular diseases;
  • Patients with uncontrolled tumor-related pain;
  • Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
  • Unexplained fever >38.5°C during the screening or before the initiation of study treatment (fever caused by tumor can be included according to the investigator);
  • History of hematopoietic stem cell transplantation or allogeneic organ transplantation;
  • History of alcohol, psychotropic substance or drug abuse;
  • History of psychiatric disorders or poor compliance;
  • History of immunodeficiency, including a positive antibody test;
  • Patients with active syphilis infection;
  • Patients with active or C;
  • According to the investigator, the underlying condition of the patient may increase the risk of receiving the drug, or cause confusion for the interpretation of the toxic reaction and AE.
  • Pregnant or lactating patients;
  • Other conditions considered unsuitable for this study by investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    PM1022

    PM1022 Injection

    Drug: PM1022

Interventions

  • DrugPM1022

    PM1022 Injection

06

What researchers measure

Primary outcomes

  1. Adverse events

    To evaluate the safety and tolerability of PM1022 in treatment of advanced tumors.

    Time frame: Up to 30 days after last treatment

07

Study locations

2 of 2 sites recruiting
  • Yan Zhang
    Jinan, Shandong, China
    Recruiting
    • Yan Zhang · Contactzhangyan0681@163.com · +86 13853110681
    • Yan Zhang · Principal investigator
    • Xudong Hu · Principal investigator
  • Ye Guo
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Apr 2024, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 22, 2023
StartActual
Apr 11, 2022
Primary completionEst.
Apr 10, 2024
CompletionEst.
Apr 10, 2025
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05867771
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Apr 11, 2022
Primary completion
Apr 10, 2024 (estimated)
Completion
Apr 10, 2025 (estimated)
Last update
May 22, 2023

Study contacts

Ye Guo
Contact
Pattrickguo@gmail.com
+86 13501678472
Ye Guo
principal investigator · Shanghai East Hospital (South Campus)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion